Abstract: Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide and 3,4,-dichloro-N-[2-(methylamino)cyclohexyl]-N-methylbenzamide, as well as the precursory immunogens, are described.

Abstract: The present invention relates to a time-resolved fluorescent immunochromatographic assay rapid test kit for quantitative determination of the level of type I pyrethroid, which has the advantages of simple operation, rapid detection, and with high accuracy. The kit has a quantitative detection limit of 9.12 ng/mL for a type I pyrethroid sample. When the kit is applied to the detection of an actual sample of type I pyrethroid and by comparing the detection result obtained by HPLC, the kit has a coefficient of correlation of 0.986 (R2). Hence, the kit is applicable to the detection by using the actual samples of type I pyrethroid.

Abstract: The invention provides a carrier and a method for obtaining, removing, or detecting extracellular membrane vesicle or virus present in a sample. In particular, the invention provides (a) a carrier (a Tim carrier) on which a protein (a Tim protein), selected from a T-cell immunoglobulin and mucin domain-containing molecule-4 (a Tim-4) protein, a Tim-3 protein, and a Tim-1 protein, is bound; (b) a method for obtaining the extracellular membrane vesicle or the virus in the sample; (c) a method for removing the extracellular membrane vesicle or the virus in the sample; (d) a method for detecting the extracellular membrane vesicle or the virus in the sample; (e) a kit for capturing the extracellular membrane vesicle or the virus, comprising the Tim carrier; and f) a kit for capturing the extracellular membrane vesicle or the virus, comprising a reagent containing the Tim protein and a reagent containing the carrier.

Abstract: Immunoassay methods and their requisite components for the detection and determination of phenethylamines of the 2C and DO sub-families are described.

Abstract: Homogeneous immunoassays that allow for compensation of background signals inherent in samples and reagents. The use of homogeneous immunoassays for the detection of the presence or amount of symmetrical Dimethyl Arginine (SDMA) in biological samples. Reagents and kits for conducting the assays.

Abstract: Disclosed herein are antibodies capable of specifically binding to tenofovir (TFV), a key small molecule drug for both the treatment and prevention of HIV, and a competitive lateral flow assay that uses these antibodies to monitor urine samples for the presence of the drug. The assay can be deployed as a point-of-care device for adherence monitoring.

Abstract: The disclosure provides compositions, kits and methods comprising an absorbent pad comprising a fibrous material and a liquid formulation comprising a luminescent substrate for identifying and quantifying biomolecule analytes.

Abstract: The present invention refers to a Raman active composite material comprising a metal particle; a coating layer of a Raman active molecule bound to the metal particle; and an encapsulating layer of an amphiphilic polymer bound to the metal particle. The present invention also refers to methods of manufacturing a Raman active composite material described herein and their uses.

Abstract: A resin-metal composite 100 to be used as a marker in an immunoassay, said resin-metal composite 100 comprising a resin particle 10 and metal particles 20 and having the following constitution (A) or constitution (B): (A) the average particle size of the resin-metal composite exceeding 300 nm; or (B) the average particle size of the metal particles being in the range of more than 20 nm and less than 70 nm. It is preferred that a part of the metal particles 20 are two- or three-dimensionally distributed in the surface layer part 60 of the resin particle 10, a part of the three-dimensionally distributed metal particles 20 are partly exposed to the outside of the resin particle 10, and a part of the remainder particles are enclosed in the resin particle 10.

Abstract: Described herein is a previously unknown function of XBP1 in triple-negative breast cancer (TNBC). It is shown that XBP1 is preferentially spliced and activated in TNBC, and that deletion of XBP1 significantly blocks triple negative breast tumor growth. Strikingly, XBP1 is required for the self-renewal of breast tumor initiating cells (TICs). Genome-wide mapping of the XBP1 transcriptional regulatory network identified a fundamental role for XBP1 in regulating the response to hypoxia via the transcription factor hypoxia-inducible factor 1? (HIF1?). Importantly, activation of this pathway appears to carry prognostic implications, as expression of the XBP1-dependent signature is associated with shorter survival times in human TNBC.

Abstract: The present invention relates to antibodies for use in detecting polymyxins and tracers; and to a single-capture immunodetection method and kits, each utilising the antibodies of the invention, and disclosed tracers.

Abstract: Compounds of general formula I wherein Fc and Fc? may be the same or different and are substituted ferrocenyl moieties having at least one ring substituent selected from sulfur-containing groups, phosphorus-containing groups, iodo, chloro, silyl, fluoroalkyl groups containing two or more fluorine atoms, heteroaryl, substituted phenyl, and cyano, wherein if present as sole substituent the cyano group is located on the proximal cyclopentadienyl ring; X is a spacer, Y is a spacer, Z is a spacer; and R is a linker group. Compound I may be used to make labelled substrates, functionalised compounds for making labelled substrates and may be used as labels in an electrochemical assay.

Abstract: The present invention relates to aqueous compositions comprising cyclodextrins or carbohydrates. The present invention also relates to the use of such compositions in the binding and removal of mycotoxins from foodstuff. The invention also includes compositions that show a broad affinity for mycotoxins.

Abstract: An immunoassay method for detecting and determining adamantane substituted indazole and indole synthetic cannabinoids is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies.

Abstract: The present invention relates to a method for detection of at least one target molecule in a blood sample comprising at least the following steps: (a) providing a blood sample; (b1) contacting said sample with an antioxidant and applying said sample to a filter to separate the blood cells from said sample; and/or (b2) applying said sample to a filter to separate the blood cells from said sample, wherein said filter comprises an antioxidant; (c) contacting said sample with a first binding molecule in the cartridge, wherein said first binding molecule is attached to a magnetic particle, and wherein said first binding molecule is capable of specifically binding to said at least one target molecule; (d) contacting said sample with a second binding molecule, wherein said second binding molecule is attached to a sensor surface, and wherein said second binding molecule is capable of specifically binding to said at least one target molecule; and (e) detecting the magnetic particles on the sensor surface.

Abstract: Disclosed is a angiogenesis inhibition determining method using MALDI mass spectrometry, and more particularly, relate to a method for detecting whether small molecules are bound with a target protein and for measuring a binding distribution between the small molecules and the target protein by comparing a result of MALDI mass spectrometry with a result of immunofluorescence of the small molecules, which are used as drugs, for the target protein, and for determining as angiogenesis is inhibited in a portion overlapping with a portion where the drug small molecules are present after the MALDI mass spectrometry in the cell or in the biosample including organelles and a portion where the target protein is present after immunofluorescence, as well as for detecting presence or absence and a distribution state of small molecules used as drugs in a sample by using MALDI mass spectrometry.

Abstract: Silica particles having a thiol group on a surface thereof, and satisfying the following conditions (a) to (c): (a) a particle diameter is 20 to 1,000 nm; (b) a density of the thiol group on the surface of the silica particles is 0.002 to 0.2 piece/nm2; and (c) a ratio (B/A) in terms of an amount B (piece/particle) of the thiol group existing on the surface of the silica particles to an amount A of sulfur elements in the silica particles (the number of sulfur elements derived from thiol per silica particle) is 0.10 to 0.60.

Abstract: An anti-equol antibody composition, containing an anti-equol antibody or antibody fragment thereof containing, as an immunoglobulin heavy chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 1-3, and as an immunoglobulin light chain variable region, hypervariable regions CDR1?, CDR2?, and CDR3? respectively including amino acid sequences represented by SEQ ID NO: 4-6; and an anti-equol antibody or antibody fragment thereof containing, as an immunoglobulin heavy chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 1-3, and as an immunoglobulin light chain variable region, hypervariable regions CDR1?, CDR2?, and CDR3? respectively including amino acid sequences represented by SEQ ID NO: 7-9.

Abstract: Antibodies, immunoassay methods and kits for the detection and determination of 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described.

Abstract: Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.